Verastem (VSTM) Short term Debt (2018 - 2024)

Verastem (VSTM) posted quarterly Short term Debt of $9.9 million for Q3 2024, up 100.37% quarter-over-quarter from $4.9 million in Q2 2024.

Analysis

Verastem (VSTM) Short term Debt (2018 - 2024) Analysis & Trends

Verastem's Short term Debt history runs 3 years deep, the most recent figure standing at $9.9 million for Q3 2024.

In Q3 2024, Short term Debt changed N/A year-over-year to $9.9 million; the TTM figure through Sep 2024 stood at $9.9 million (changed N/A YoY), while the FY2018 annual figure was $5.7 million, changed N/A from the prior year.
Short term Debt for Q3 2024 stood at $9.9 million, up from $4.9 million in the prior quarter.
The five-year high for Short term Debt was $9.9 million in Q3 2024, with the low at $4.6 million in Q2 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Verastem	814.94 Mn	678.59 Mn	36.32 Mn

Historic Data

Download Data